Knee osteoarthritis drug trial ends early – what we know

NCT ID NCT04520607

Terminated Disease control Sponsor: Biosplice Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called lorecivivint, given as a knee injection, to see if it could safely slow knee osteoarthritis and improve pain and function over two years. It enrolled 276 people who had already completed an earlier study. The trial was terminated early, so the full results are not available. The drug aims to control the disease rather than cure it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lorecivivint (a drug injected into the knee joint)
What this could lead to: If it works, this could point toward a treatment that slows knee osteoarthritis and eases pain and stiffness.
What could go wrong: This trial was terminated early, so results are limited. It is a Phase 3 study, but the drug may not work better than placebo, and injections carry risks like pain or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOARTHRITIS, KNEE

Contacts and locations

Locations

Research Site

Tucson, Arizona, 85712, United States
Research Site

Anaheim, California, 92805, United States
Research Site

Pomona, California, 91767, United States
Research Site

San Diego, California, 92103, United States
Research Site

Thousand Oaks, California, 91360, United States
Research Site

Denver, Colorado, 80209, United States
Research Site

Hialeah, Florida, 33016, United States
Research Site

Miami, Florida, 33173, United States
Research Site

Miami Lakes, Florida, 33014, United States
Research Site

Port Orange, Florida, 32127, United States
Research Site

West Palm Beach, Florida, 33409, United States
Research Site

Winter Haven, Florida, 33880, United States
Research Site

Winter Park, Florida, 32789, United States
Research Site

Newnan, Georgia, 30265, United States
Research Site

Woodstock, Georgia, 30189, United States
Research Site

Gurnee, Illinois, 60031, United States
Research Site

Oak Brook, Illinois, 60523, United States
Research Site

Valparaiso, Indiana, 46383, United States
Research Site

New Orleans, Louisiana, 70124, United States
Research Site

Bay City, Michigan, 48706, United States
Research Site

Troy, Michigan, 48085, United States
Research Site

Hazelwood, Missouri, 63042, United States
Research Site

St Louis, Missouri, 63141, United States
Research Site

Omaha, Nebraska, 68114, United States
Research Site

Hartsdale, New York, 10530, United States
Research Site

New York, New York, 10016, United States
Research Site

Rochester, New York, 14609, United States
Research Site

Charlotte, North Carolina, 28209, United States
Research Site

Salisbury, North Carolina, 28144, United States
Research Site

Winston-Salem, North Carolina, 27103, United States
Research Site

Cincinnati, Ohio, 45242, United States
Research Site

Columbus, Ohio, 43235, United States
Research Site

Oklahoma City, Oklahoma, 73103, United States
Research Site

Fort Mill, South Carolina, 29707, United States
Research Site

Mt. Pleasant, South Carolina, 29464, United States
Research Site

Rapid City, South Dakota, 57702, United States
Research Site

Carrollton, Texas, 75007, United States
Research Site

Plano, Texas, 75075, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Draper, Utah, 84020, United States
Research Site

Salt Lake City, Utah, 84107, United States
Research Site

Charlottesville, Virginia, 22911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.